Aviva M. Tolkovsky

Aviva M. Tolkovsky

Auto-generated profile, based on publicly available information

Aviva M. Tolkovsky

Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge, CB2 0AH, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Cell Reports
Verified
Journal Article
Open access
JBJack Brelstaff
Jack Brelstaff
ATAviva M. Tolkovsky
Aviva M. Tolkovsky
BGBernardino Ghetti
Bernardino Ghetti
MGMichel Goedert
Michel Goedert
MSMaria Grazia Spillantini
Maria Grazia Spillantini
Tau protein forms insoluble filamentous inclusions that are closely associated with nerve cell death in many neurodegenerative diseases. How neurons die in these tauopathies is unclear. We report that living neurons with tau inclusions from P301S-tau mice expose abnormally high amounts of phosphatidylserine because of the production of reactive oxygen species (ROS). Consequently, co-cultured phagocytes (BV2 cells or primary microglia) identify and phagocytose the living neurons, thereby engulfing insoluble tau inclusions. To facilitate engulfment, neurons induce contacting microglia to secrete the opsonin milk-fat-globule EGF-factor-8 (MFGE8) and nitric oxide (NO), whereas neurons with tau inclusions are rescued when MFGE8 or NO production is prevented. MFGE8 expression is elevated in transgenic P301S-tau mouse brains with tau inclusions and in tau inclusion-rich brain regions of several human tauopathies, indicating shared mechanisms of disease. Preventing phagocytosis of living neurons will preserve them for treatments that inhibit tau aggregation and toxicity.

22 October 2021 in Science Advances
Verified
Journal Article
Open access
JBJack H. Brelstaff
Jack H. Brelstaff
MMMatthew Mason
Matthew Mason
Taxiarchis KatsinelosTaxiarchis Katsinelos
Taxiarchis Katsinelos
WMWilliam Mcewan
William Mcewan
BGBernardino Ghetti
Bernardino Ghetti
MSMaria Grazia Spillantini
Maria Grazia Spillantini
Microglia change their behavior when eating live neurons containing tau protein aggregates, a hallmark of Alzheimer’s disease.

13 November 2013 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MMManuela Mellone
Manuela Mellone
DKDimitra Kestoras
Dimitra Kestoras
Melissa AndrewsMelissa Andrews
Melissa Andrews
EDElisa Dassie
Elisa Dassie
RCR. Anthony Crowther
R. Anthony Crowther
MSMaria Grazia Spillantini
Maria Grazia Spillantini
Intracellular tau aggregates are the neuropathological hallmark of several neurodegenerative diseases, including Alzheimer's disease, progressive supranuclear palsy, and cases of frontotemporal dementia, but the link between these aggregates and neurodegeneration remains unclear. Neuronal models recapitulating the main features of tau pathology are necessary to investigate the molecular mechanisms of tau malfunction, but current models show little and inconsistent spontaneous tau aggregation. We show that dorsal root ganglion (DRG) neurons in transgenic mice expressing human P301S tau (P301S-htau) develop tau pathology similar to that found in brain and spinal cord and a significant reduction in mechanosensation occurs before detectable fibrillar tau formation. DRG neuronal cultures established from adult P301S-htau mice at different ages retained the pattern of aberrant tau foundin vivo. Moreover, htau became progressively hyperphosphorylated over 2 monthsin vitrobeginning with nonsymptomatic neurons, while hyperphosphorylated P301S-htau-positive neurons from 5-month-old mice cultured for 2 months died preferentially. P301S-htau-positive neurons grew aberrant axons, including spheroids, typically found in human tauopathies. Neurons cultured at advanced stages of tau pathology showed a 60% decrease in the fraction of moving mitochondria. SEG28019, a novel O-GlcNAcase inhibitor, reduced steady-state pSer396/pSer404 phosphorylation over 7 weeks in a significant proportion of DRG neurons showing for the first time the possible beneficial effect of prolonged dosing of O-GlcNAcase inhibitorin vitro. Our system is unique in that fibrillar tau forms without external manipulation and provides an important new tool for understanding the mechanisms of tau dysfunction and for screening of compounds for treatment of tauopathies.

29 May 2015 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
JBJack Brelstaff
Jack Brelstaff
BOBernardino Ossola
Bernardino Ossola
JNJonas J. Neher
Jonas J. Neher
TKTherã©Se Klingstedt
Therã©Se Klingstedt
KNK. Peter R. Nilsson
K. Peter R. Nilsson
ATAviva M. Tolkovsky
Aviva M. Tolkovsky
Identification of fluorescent dyes that label filamentous protein aggregates characteristic of neurodegenerative disease, such as β-amyloid and tau in Alzheimer’s disease (AD), in a live cell culture system has previously been a major hurdle. Here we show that pentameric formyl thiophene acetic acid (pFTAA) fulfils this function in living neurons cultured from adult P301S tau transgenic mice. Injection of pFTAA into 5-month-old P301S tau mice detected cortical and DRG neurons immunoreactive for AT100, which identifies solely filamentous tau, or MC1, which identifies a conformational change in tau that is commensurate with neurofibrillary tangle formation in AD brains. In fixed cultures of dorsal root ganglion (DRG) neurons, pFTAA binding, which also identified AT100 or MC1+ve neurons, followed a single, saturable binding curve with a half saturation constant of 0.14 µM, the first reported measurement of a binding affinity of a beta-sheet reactive dye to primary neurons harbouring filamentous tau. Treatment with formic acid, which solubilises filamentous tau, extracted pFTAA, and prevented the re-binding of pFTAA and MC1 without perturbing expression of soluble tau, detected using an anti-human tau (HT7) antibody. In live cultures, pFTAA only identified DRG neurons that, after fixation, were AT100/MC1+ve, confirming that these forms of tau pre-exist in live neurons. The utility of pFTAA to discriminate between living neurons containing filamentous tau from other neurons is demonstrated by showing that more pFTAA+ve neurons die than pFTAA-ve neurons over 25 days. Since pFTAA identifies fibrillar tau and other misfolded proteins in living neurons in culture, in animal models of several neurodegenerative diseases, and in human brains, it should have considerable application in sorting out disease mechanisms and in identifying disease-modifying drugs that will ultimately help establish the mechanisms of neurodegeneration in human neurodegenerative diseases.

1 July 1991 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
ABA. Buckmaster
A. Buckmaster
CNC. D. Nobes
C. D. Nobes
SES. N. Edwards
S. N. Edwards
ATA. M. Tolkovsky
A. M. Tolkovsky

11 August 2003 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
HYHong Wa Yung
Hong Wa Yung
ATAviva M. Tolkovsky
Aviva M. Tolkovsky
We have examined the relationship between adenosine triphosphate (ATP) concentration and loss of maintenance of kinase‐signalling cascades in primary cortical astrocytes during oxygen–glucose depriva...